Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season

Background. We estimated the effectiveness of inactivated influenza vaccines for the prevention of laboratory-confirmed, medically attended influenza during 3 seasons with variable antigenic match between vaccine and patient strains. Methods. Patients were enrolled during or after a clinical encounter for acute respiratory illness. Influenza infection was confirmed by culture or reverse-transcriptase polymerase chain reaction. Case-control analyses were performed that used data from patients who were ill without influenza (hereafter, “test-negative control subjects”) and data from asymptomatic control subjects from the population (hereafter, “traditional control subjects”). Vaccine effectiveness (VE) was estimated as [100 × (1 − adjusted odds ratio)]. Influenza isolates were antigenically characterized. Results. Influenza was detected in 167 (20%) of 818 patients in 2004–2005, in 51 (14%) of 356 in 2005–2006, and in 102 (11%) of 932 in 2006–2007. Analyses that used data from test-negative control subjects showed that VE was 10% (95% confidence interval [CI], −36% to 40%) in 2004–2005, 21% (95% CI,−52% to 59%) in 2005–2006, and 52% (95% CI, 22% to 70%) in 2006–2007. Using data from traditional control subjects, VE for those seasons was estimated to be 5% (95% CI, −52% to 40%), 11% (95% CI, −96% to 59%), and 37% (95% CI, −10% to 64%), respectively; confidence intervals included 0. The percentage of viruses that were antigenically matched to vaccine strains was 5% (3 of 62) in 2004–2005, 5% (2 of 42) in 2005–2006, and 91% (85 of 93) in 2006–2007. Conclusions. Influenza VE varied substantially across 3 seasons and was highest when antigenic match was optimal. VE estimates that used data from test-negative control subjects were consistently higher than those that used data from traditional control subjects.